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Signaling pathwaysFerulic acid (FA, 4-hydroxy-3-methoxycinnamic acid) is a phytochemical compound naturally present in
several plants and foods that is approved as an antioxidant additive and food preservative. It exerts a beneﬁcial
action in chronic mild stress-induced depressive-like behavior and produces an acute antidepressant-like effect
in the tail suspension test (TST) through the activation of the serotonergic system. This studywas aimed at inves-
tigating the possible involvement of signaling pathways in the antidepressant-like effect of acute and oral admin-
istration of FA, in the TST in mice. The anti-immobility effect of orally administered FA (0.01 mg/kg, p.o.) was
prevented by pretreatment of mice with H-89 (1 μg/site, i.c.v., an inhibitor of PKA), KN-62 (1 μg/site, i.c.v., an
inhibitor of CaMKII), GF109203X (5 ng/site, i.c.v., an inhibitor of PKC), U0126 (5 μg/site, i.c.v., an inhibitor of
MAPK/ERK) or LY294002 (10 nmol/site, i.c.v., an inhibitor of PI3K), all involved with neurotrophic signaling
pathways. The results demonstrated that FA exerts antidepressant-like effect in the TST in mice, through the
activation of signaling pathways related to neuroplasticity, neurogenesis and cell survival.
© 2012 Elsevier Inc. Open access under the Elsevier OA license.1. Introduction
Ferulic acid (FA, 4-hydroxy-3-methoxycinnamic acid, Fig. 1A) is
a phenolic compound present in several plants and in natural
extracts of medicinal plants, spices, chocolate and coffee (Graf,
1992; Virgili et al., 2000). In Japan FA has been approved as an
antioxidant additive and food preservative (Graf, 1992; JFCRF,
1996). Moreover, FA, as sodium ferulate, has been popularly used
for the treatment of cardiovascular and cerebrovascular diseases
also approved by the State Drugs Administration of China (Wang
and Ou-Yang, 2005).
Interestingly, FA is a phytochemical, which exhibits antioxidant
and anti-inﬂammatory properties that may be used in the therapy
for neurodegenerative diseases. In addition, FA produced a potent
protection against excitotoxic effects of glutamate monosodium, a
result that may indicate that FA is an N-methyl-D-aspartate (NMDA)
receptor antagonist (Yu et al., 2006). FA has also shown to affect
cell cycle, by increasing proliferation of neural stem/progenitor
cells in vitro and in vivo. It has also been reported to ameliorate the
stress-induced depression-like behavior in mice (Yabe et al., 2010)Naturais, Universidade Re-
SC, Brazil. Tel.: +55 47 3321
om (A.L.B. Zeni).
ier OA license.and exerted antidepressant-like behavior in mice through the in-
volvement of the serotonergic system (Zeni et al., 2012). Previously,
Zhang et al. (2011a) showed FA-induced anti-immobility effect in
rats in the forced swimming test (FST) and Zhang et al. (2011b) dem-
onstrated that sodium ferulate (sodium salt of FA) also exerts
antidepressant-like effect, in mice or rats using TST and FST tests or
chronic mild stress (CMS) model, respectively.
Depression treatment with the available medications provides a
complete remission just for 50–60% of the patients (Nestler et al.,
2002). Additionally, they are hindered by adverse side effects and are
slow to produce beneﬁcial effects (Rush et al., 2006). Therefore, it is
necessary to continue the search for novel molecules that have a
potential antidepressant effect. FA has been reported to have many
pharmacological effects such as, antioxidant, neuroprotective and
anti-inﬂammatory (Graf, 1992; Zhang et al., 2011b; Murakami et al.,
2002). Moreover positive pre-clinical effects have been found in FA in
diseases that have a link between neurodegeneration and excitotoxicity
(Perluigi et al., 2006). Considering the lack of studies dealing with the
signaling pathways implicated in the antidepressant-like effect of FA,
this study sought to investigate the hypothesis that its effect in the
TST would be mediated through the modulation of protein kinase A
(PKA), Ca2+/calmodulin-dependent protein kinase II (CaMKII), protein
kinase C (PKC), mitogen-activated protein kinase/extracellular signal-
regulated kinase (MAPK/ERK) or phosphatidylinositol-3-kinase (PI3K)
pathways.
Fig. 1. Evaluation of the involvement of signaling pathways in the antidepressant-like effect of ferulic acid (FA) in the tail suspension test (TST) in mice. Chemical structure of FA (A).
Effect of the pretreatment of mice with H-89 (a PKA inhbibitor, 1 μg/site, i.c.v.) (B), KN-62 (a CaMKII inhibitor, 1 μg/site, i.c.v.) (C), GF1090203X (a PKC inhibitor, 5 ng/site, i.c.v.)
(D), U0126 (a MAPK/ERK inhibitor, 5 μg/site, i.c.v.) (E) or LY294002 (a PI3K inhibitor, 10 nmol/site, i.c.v.) (F) on the anti-immobility action of FA (0.01 mg/kg, p.o.) in the TST.
Values are expressed as mean±S.E.M. (n=6–7). **P≤0.01 compared with the vehicle-treated control group; #Pb0.01 compared with the same group pre-treated with vehicle
(two-way ANOVA followed by Tukey's HSD test).
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2.1. Animals
Male Swiss mice (30–40 g) were maintained at 21–23 °C with free
access to water and food, under a 12:12 h light/dark cycle (lights on
at 07:00 h). All manipulations were carried out between 9:00 and
16:00 h, with each animal used only once. All procedures in this
study were performed in accordance with the National Institute of
Health Guide for the Care and Use of Laboratory Animals. The exper-
iments were performed after the approval of the protocol by the Insti-
tutional Ethics Committee (CEUA/UFSC-23080.004955/2009-35) and
all efforts were made to minimize animals suffering and to reduce
the number of animals used in the experiments.
2.2. Drugs and administration
Ferulic acid (FA), N-[2-(p-bromocinnamylamino) ethyl]-5-
isoquinolinesulfonamide (H-89),4-[2-[(5-isoquinolinyl-sulfonyl)methyl-amino]-3-oxo-3-(4-phenyl-1-piperazinyl) propyl] phenyl ester
(KN-62), bisindoylmaleimide I (GF109203X), 1,4-diamino-2,3-dicyano-
1,4-bis [2-aminophenylthio] butadiene (U0126) and 2-(4-morpholino)-
8-phenyl-4H-1-benzopyran-4-one (LY294002—all from Sigma Chemical
Company, St. Louis, MO, U.S.A.) were used. Drugswere dissolved in saline
except ferulic acid that was diluted in saline with 1% Tween 80. Control
animals received appropriate vehicle.
The signaling pathway inhibitors were administered by intra-
cerebroventricular (i.c.v.) route. I.c.v. administration was performed
under light ether anesthesia as previously described (Brocardo et al.,
2008). A 0.4 mm external diameter hypodermic needle was brieﬂy
attached to a cannula, which was linked to a 25 μl Hamilton syringe,
inserted perpendicularly through the skull no more than 2 mm into
the brain of the mouse. A volume of 5 μl was then administered in
the left lateral ventricle. The injection was given over 30 s, and the
needle remained in place for another 30 s in order to avoid the reﬂux
of the substances injected. The injection site was 1 mm to the right or
left from the mid-point on a line drawn through to the anterior base
of the ears.
Table 1
Effect of ferulic acid and signaling pathways inhibitors on the number of crossings in
the open-ﬁeld test in mice.
Experimental groups Number of crossings
Vehicle 80.5±3.9
Ferulic acid 76.2±3.6
H-89 71.3±3.3
Ferulic acid×H-89 74.7±3.1
KN-62 70.2±3.8
Ferulic acid×KN-62 71.0±3.4
GF1090203X 78.0±7.9
Ferulic acid×GF1090203X 77.0±6.8
U0126 76.7±2.7
Ferulic acid×U0126 75.8±2.7
LY294002 76.7±2.8
Ferulic acid×LY294002 72.8±2.4
Effect of the pretreatment of mice with H-89 (1 μg/site), KN-62 1 μg/site), GF1090203X
(5 ng/site), U0126 (5 μg/site) or LY294002 (10 nmol/site) followed by ferulic acid
(0.01 mg/kg, p.o.) or vehicle on the number of crossings in the open-ﬁeld test. Values
are expressed as mean±S.E.M. (n=6).
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FA in the TST is mediated through the activation of PKA, CaMKII, PKC,
MAPK/ERK or PI3K, mice were pre-treated by i.c.v. route, with vehicle
or H-89 (1 μg/site), KN-62 (1 μg/site), GF109203X (5 ng/site), U0126
(5 μg/site) or LY294002 (10 nmol/site), respectively. Fifteen minutes
after pre-treatment vehicle or FA (0.01 mg/kg, p.o.) was orally ad-
ministered, and within 30 min later the TST was carried out.
The doses of the drugs used were selected on the basis of literature
data and from previous results from our laboratory and are reported
not to increase locomotor activity (Stemmelin et al., 1999; Vianna et
al., 2000; Narita et al., 2002; Sato et al., 2004; Almeida et al., 2006;
Ueno et al., 2006).
2.3. Tail suspension test (TST)
The total duration of immobility induced by tail suspension was
measured according to the method of Steru et al. (1985). Mice both
acoustically and visually isolated were suspended 50 cm above the
ﬂoor by adhesive tape placed approximately 1 cm from the tip of
the tail. Immobility time was recorded during a 6-min test (Machado
et al., 2007; Rodrigues et al., 2002). Mice were considered immobile
only when they hung passively and completely motionless. The immo-
bility time was recorded by an observer blind to the drug treatment.
2.4. Open-ﬁeld test
The ambulatory behavior was assessed in an open-ﬁeld test as
described by Zomkowski et al. (2010). The open ﬁeld arena used
was a wooden box (40×60×50 cm) with the ﬂoor divided into 12
equal squares. At the start of each trial a mouse was placed in the
left corner of the ﬁeld and was allowed to freely explore the arena.
The number of squares crossed with all paws (crossing) was counted
in a 6 min session. The arena ﬂoor was cleaned between the trials
with a 10% ethanol solution and the test was carried out in a temper-
ature, noise and light controlled room.
2.5. Data analysis
Comparisons between treatment groups and control were performed
by one-way or two-way analyses of variance (ANOVA) followed by
Tukey's honestly signiﬁcant difference (HSD) test when appropriate.
Data are expressed as mean as S.E.M. and the value of Pb0.05 was
considered to be signiﬁcant.
3. Results
3.1. Effect of the pretreatment with signaling pathways inhibitors on the
FA antidepressant-like effect in the TST
We have previously shown that FA (0.01 mg/kg, p.o.) induced a
reduction in the immobility time in the TST in mice, thus showing
an antidepressant-like effect of FA (Zeni et al., 2012). In this study,
we have evaluated the putative signaling pathways involved in the
antidepressant-like effect of FA.
Fig. 1B shows that the pretreatment with H-89 (1 μg/site, i.c.v., an
inhibitor of PKA), signiﬁcantly (Pb0.01) inhibited the decrease in the
immobility time caused by FA in the TST. A two-way ANOVA revealed
a main effect of pretreatment [F (1,24)=15.01, Pb0.01], treatment
[F (1,24)=17.29, Pb0.01] and of treatment×pretreatment interaction
[F (1,24)=18.27, Pb0.01]. Fig. 1C shows the effect of pretreatment
with KN-62 (1 μg/site, i.c.v., an inhibitor of CaMKII) on the reduction
of immobility time elicited by FA. A two-way ANOVA revealed signiﬁ-
cant differences of pretreatment [F (1,24)=9.86, Pb0.01], treatment
[F (1,24)=36.65, Pb0.01], and of treatment×pretreatment interaction
[F (1,24)=21.23, Pb0.01].The results depicted in Fig. 1D shows the inﬂuence of pretreatment
GF109203X (5 ng/site, i.c.v., an inhibitor of PKC) on the reduced
anti-immobility effect of FA in the TST. A two-wayANOVA showed a sig-
niﬁcant effect of pretreatment [F (1,20)=4.57, Pb0.01], treatment
[F (1,20)=19.42, Pb0.01], and of treatment×pretreatment interaction
[F (1,20)=8.81, Pb0.01]. Fig. 1E shows the effect of pretreatment with
U0126 (5 μg/site, i.c.v., an inhibitor of MAPK/ERK speciﬁcally, MEK1/2)
on the reduction in immobility time elicited by FA in the TST. A two-way
ANOVA showed a signiﬁcant effect of pretreatment [F (1,20)=25.44,
Pb0.01], treatment [F (1,20)=16.16, Pb0.01, and of treatment×
pretreatment interaction [F (1,20)=25.20, Pb0.01]. Fig. 1F shows the
effect of pretreatment with LY294002 (10 nmol/site, i.c.v., an inhibitor
of PI3K) in the anti-immobility effect exerted by FA in the TST.
A two-way ANOVA showed a signiﬁcant effect of pretreatment
[F (1,24)=8.36, Pb0.01], treatment [F (1,24)=10.06, Pb0.01], and of
treatment×pretreatment interaction [F (1,24)=19.17, Pb0.01].
3.2. Effects of FA and inhibitors of signaling pathways on the locomotor
activity in the open-ﬁeld test
The results illustrated in Table 1 show the analysis of the locomo-
tor activity observed in the open-ﬁeld test after i.c.v. administration
of H-89 (1 μg/site), KN-62 (1 μg/site), GF109203X (5 ng/site),
U0126 (5 μg/site) or LY294002 (10 nmol/site) alone or in combina-
tion with FA. This administration of inhibitors alone or in combina-
tion with FA did not affect the ambulation in the open-ﬁeld test. A
two-way ANOVA did not reveal signiﬁcant differences for the pre-
treatment, treatment and interaction (data not shown).
4. Discussion
The research and development of more effective and faster re-
sponse to antidepressant therapies is necessary since antidepressants
remain inadequate for several individuals and a delay of several
weeks in order to achieve its clinical efﬁcacy are the main points in
quitting the treatments by patients.
FA has low toxicity and the acute oral DL50 in male F344 rats was
2.4 g/kg as determined by Tada et al. (1999). Chang et al. (1993) have
previously reported that free FA was recovered in several organs,
including brain, at approximately 30 min after oral administration
of FA in rats. Such observations were recently conﬁrmed by Zhang
et al. (2011a), showing that FA reached the hippocampus 30 min
after oral administration in rats.
FA has been previously shown to exert an antidepressant-like
effect, in CMS-induced depressive-like behavior in mice (Yabe et al.,
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serotonergic system (Zhang et al., 2011a; Zeni et al., 2012). Zhang et
al. (2011b) also observed the antidepressant-like effect with sodium
ferulate in mice and rats. However, the role of signaling pathways in
anti-immobility effect of FA has not yet been investigated. In the pres-
ent study, the involvement of signaling cascades implicated in the
pathophysiology of depressive disorders, namely PKA, CaMKII, PKC,
MAPK/ERK and PI3K, in the antidepressant-like effect of FA in the
TST in mice was investigated.
A wide variety of standard antidepressant treatments (e.g.
noradrenaline-reuptake inhibitors, selective serotonin-reuptake in-
hibitors and electroconvulsive seizures) increase the cAMP response
element binding protein (CREB) activity (Nibuya et al., 1996; Song
et al., 1997). Furthermore, accumulating evidence suggests that
roles for CREB-regulated expression of neural growth factors, as for
instance, the increased expression of brain-derived neurotrophic fac-
tor (BDNF) in humans treated with antidepressants (Hashimoto,
2010). Accordingly, Okamoto et al. (2003) reported that administra-
tion of amitriptyline increased BDNF protein levels and Yu et al.
(2011) showed that sodium ferulate also up-regulated the expression
of BDNF inducing cell proliferation in the rat hippocampus.
Modulation of diverse protein kinases directly or indirectly
converges to the activation of CREB, mainly through PKA, CaMKII
and MAPK as well as PI3K and PKC activation (Mathew et al., 2008;
Pittenger and Duman, 2008). These studies have suggested that the
ability to control a signaling process eventually yields therapeutic
approaches to treat mood disorders, perhaps with the decrease on
the onset treatment of depression.
In this work the reduction of immobility time in TST elicited by FA
was fully abolished by the pretreatment of mice with H-89, a
compound which acts as a competitive inhibitor at the ATP binding
site in the catalytic subunit of PKA. It has been reported that PKA is
involved in several functions in the brain, including synthesis and
release of neurotransmitters, gene expression, memory and, cell
growth, differentiation and survival (Gould and Manji, 2002). The
major mechanism of PKA-mediated function is through the phos-
phorylation of substrates as CREB that modulates the activation of
proteins such as BDNF, implicated in cell survival and neuronal
plasticity (D'as and Duman, 2002).
In addition, we showed that the acute antidepressant-like effect of
FA was signiﬁcantly reversed by the pretreatment of mice with KN-62,
a selective inhibitor of CaMKII that did not cause an effect in the TST
per se. This result indicates that the antidepressant-like effect of FA is as-
sociated with the activation of CaMKII. Our results are in agreement
with the fact that CaMKII may play an important role in the pathophys-
iology and treatment of many stress-related disorders (Du et al., 2004).
Suggesting an important role in the pathophysiology of depres-
sion, it was observed that protein kinase C (PKC) activity is sig-
niﬁcantly decreased in the prefrontal cortex and hippocampus of
teenage suicide victims (Pandey et al., 2004). Our data demonstrated
that antidepressant-like effect of FA was also prevented by the
pretreatment with GF109203X, a selective agent that is competitive
to the ATP binding site on the catalytic domain of PKC, suggesting
that this signaling pathway is involved in antidepressant-like action
of FA in the TST.
According to Adayev et al. (2005), it is expected that 5-HT recep-
tors (e.g., 5-HT1 and 5-HT2 receptors), which mediate the activation
of ERK1/2 could play an important role in proliferation, differentiation
and protection of brain cells. The present study demonstrated the in-
volvement of the MAPK/ERK pathway in the acute antidepressant-like
effect of FA in the TST. The results showed that the pretreatment of
mice with a selective extracellular permeable inhibitor of MAPK/ERK,
U0126, at a dose that did not produce any effect in the TST, signiﬁcantly
inhibited the anti-immobility effect of FA. This result may indicate that
the antidepressant-like effect of FA is possibly due to the activation of
the MAPK/ERK pathway. In addition, U0126 has been shown to inhibitERK-inducing depressive-like behavior (Qi et al., 2009) and also has
blocked the antidepressant effects of BDNF (Shirayama et al., 2002),
suggesting that this signaling pathway plays a role in the therapeutic
action of antidepressants.
PI3K/Akt signaling has also been shown to be implicated in the
mechanism of action of antidepressant drugs (Beaulieu et al., 2009).
Previous observations have suggested a close association between
hippocampal neurogenesis and the pathology of depression, since
hippocampal neurogenesis seems to be required for the behavioral
recovery effects of antidepressant treatments (Czeh et al., 2001;
Santarelli et al., 2003).
Not surprisingly, when we used LY294002 (an inhibitor of PI3K
pathway), it prevented the reduction of immobility time exerted by
FA. Accordingly, GSK-3β phosphorylation, a target for Akt activity, is
reduced by the PI3K inhibitor (Shapira et al., 2007), and treatment
with selective GSK-3β inhibitors produced antidepressant-like effect
in the FST in mice (Gould et al., 2004; Rosa et al., 2008).
The reversal of the antidepressant-like effect of FA in the TST
observed here in the presence of signaling pathway inhibitors is not
due to any alteration in the locomotor activity, since the administration
of H-89, KN-62, GF109203X, U0126 and LY294002 alone or in combina-
tion with FA did not signiﬁcantly alter the locomotor activity of mice.
Long-term administration of sodium ferulate was capable of
preventing amyloid β-induced neurotoxicity through activation and
up-regulation of ERK and Akt in the rats' hippocampus (Jin et al.,
2005). In the aged rats' hippocampus, sodium ferulate was able to
exert neuroprotection through suppression of IL-1β and IL-1β-induced
JNK signaling and also via up-regulation of ERK and Akt survival path-
ways (Jin et al., 2008). These studies point towards a close correlation
between neuroprotective and antidepressants-like actions of FA.
The inﬂuence of FA exerts on the serotonergic neurotransmission
was highlighted in a recent publication of Zhang et al. (2011a) who
demonstrated that FA exerted antidepressant-like effect and signiﬁ-
cantly increased 5-HT in hippocampus, conﬁrming simultaneously anti-
depressant and prokinectic effects of FA in the FST in rats. Furthermore
we have recently shown that pretreatment with WAY100635 or
ketanserin was able to reverse the antidepressant-like effect of FA in
the TST in mice. Moreover, a synergistic antidepressant-like effect of
FA with selective serotonin reuptake inhibitor (SSRI) antidepressants
was shown (Zeni et al., 2012). Furthermore, Yu et al. (2006) suggested
that FA is a novel competitive antagonist of NMDA receptors, and antag-
onists of these receptors have been reported to increase serotonin
release in the brain (Callado et al., 2000; Tso et al., 2004; Gaikwad
et al., 2005). Accordingly, the administration of antidepressants that
increases levels of serotonin at the synapse activates CREB by triggering
different signaling transduction pathways, i.e., PKA, MAPK and CaMKII
pathways (D'as and Duman, 2002). In fact, oral administration of FA
was capable to increase CREB phosphorylation and BDNFmRNAexpres-
sion in mice (Yabe et al., 2010— Fig. 2).
In conclusion, our study provides evidence of the involvement of
known signaling pathways in the acute antidepressant-like effect of
FA in the TST. Moreover, the effect of FA is prevented by selective
inhibitors of several signaling cascades, involving modulation of
synaptic plasticity, neurogenesis and cell survival (D'as and Duman,
2002; Hashimoto, 2010) that might culminate in the antidepressant-
like effect of FA. Diverse ﬁndings support the hypothesis that neuro-
nal loss as well as oxidative stress and inﬂammation contribute
signiﬁcantly to the pathophysiology of mood disorders (Maes et al.,
2011). Therefore, the results showed here suggest that FA could be
further investigated as a potential antidepressant or an additive
polypharmacological therapeutic strategy.
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